3 Dividend Stocks Built for Retirement to Buy in August
Bond yields are retreating, growth stocks pay nothing, and retirement portfolios need income that holds up whether the AI boom accelerates or crashes. Three dividend growers sit quietly at the center of that infrastructure story, and most retirees have overlooked…
Retirement portfolios in August 2026 face a specific puzzle. Bond yields have come off their highs, equity valuations remain elevated, and the biggest secular story in markets, AI infrastructure, is dominated by expensive growth names that pay little or nothing in income. The workaround is to own the picks-and-shovels businesses that get paid whether the AI boom accelerates or cools: the healthcare franchises funding oncology innovation, the industrial landlords collecting rent on the warehouses and power sites feeding data campuses, and the interconnection hubs where the compute actually happens.
Below are three dividend growers built for retirement income, each with a direct line to the AI infrastructure build and a track record of hiking payouts through cycles.
Johnson & Johnson (NYSE: JNJ)
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is the anchor position. The healthcare giant carries a market cap of roughly $613 billion and trades at $254.41, up 24.3% year to date and 55.84% over the past year. The forward multiple sits at 24 on forward EPS of $11.29, reasonable for a Dividend King with an AAA-rated balance sheet.
The income case is straightforward. The board pushed the quarterly payout to $1.34 per share, with the next ex-dividend date on August 25, 2026 and payment on September 8, 2026. That marks 64 consecutive years of increases, a streak few US companies can match. The annualized forward dividend of $5.36 gives retirement holders a base of predictable cash flow.
Why does JNJ belong in an AI-adjacent retirement basket? Oncology. Q1 2026 revenue reached $24.06 billion, up 9.9% year over year, with DARZALEX at $3.96 billion (+22.5%) and TREMFYA at $1.61 billion (+68.3%). Management is targeting $50 billion in oncology revenue by 2030, and computational drug discovery is core to the pipeline. CEO Joaquin Duato said the company "had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact."
The risk: STELARA biosimilar erosion continues to weigh on the Innovative Medicine segment, with Q1 sales down 59.7%. The next earnings report lands October 14, 2026, and any softness in oncology growth would test the current premium multiple.
Prologis (NYSE: PLD)
Prologis (NYSE:PLD) is the logistics REIT quietly turning into a hybrid data center landlord. Shares trade at $144.15, up 14.66% year to date and 41.87% over one year, with a market cap of roughly $134 billion.
The Q2 2026 report was the tell. Revenue hit $2.43 billion, up 11.1%, with record leasing above 67 million square feet and same-store cash NOI up 8.5%. More importantly, Prologis reported a 5.8 GW data center power pipeline and $802 million in data center development starts, 100% pre-leased. CEO Daniel Letter framed it plainly: "Customer demand is broadening, and our opportunity set is expanding as logistics, digital infrastructure and energy needs increasingly intersect."
The dividend growth is on solid ground. PLD paid $1.07 per share in Q2 2026, up from $1.01 a year earlier. This is 13 consecutive years of dividend increases (short of Aristocrat status, but the trajectory is intact). The bigger picture: every $1 trillion in data center capex is estimated to generate 30 to 40 million square feet of additional logistics demand, with McKinsey projecting data center capex near $7 trillion by 2030. Prologis owns the ground and increasingly the megawatts to serve it.
The risk: Beta of 1.34 makes PLD more volatile than income investors typically prefer, and $36.4 billion in consolidated debt means refinancing costs matter if rates back up.
Equinix (NASDAQ: EQIX)
Equinix (NASDAQ:EQIX) is the direct AI infrastructure income play. Shares trade at $1,031.44, up 36% year to date, with a market cap near $102 billion. Analyst sentiment is emphatic: 81% bullish, 25 buy or strong buy ratings, with an average target of $1,220.14.
Q2 2026 results (reported July 29) delivered revenue of $2.63 billion, up 16.4% year over year, adjusted EBITDA of $1.40 billion at 53% margin, and a record 9,700 net interconnections added. Management raised FY2026 revenue guidance to $10.21 billion to $10.29 billion and AFFO per share to $42.69 to $43.29. CEO Adaire Fox-Martin noted "monthly recurring revenue grew double digits for the third straight quarter."
The dividend was hiked to $5.16 per quarter, up from $4.69 in 2025, with the next ex-date on August 19, 2026 and payment on September 16, 2026. Management guides long-term dividend growth to track AFFO growth of 9% to 12% annually. For a retiree with a 10-year horizon, that compounding is the entire point.
The risk: Power procurement costs, capex of $5.0 to $6.0 billion in 2026, and a forward P/E of 44 leave less room for execution slips than JNJ or PLD.
The Setup Into Fall
Three names, three ways to own AI infrastructure through dividends rather than momentum. JNJ delivers defensive cash flow at low beta of 0.235. PLD sits at the intersection of e-commerce logistics and hyperscale power. EQIX is the interconnection layer where AI workloads route. All three have raised payouts in 2026, and all three have ex-dividend dates on the calendar before the October earnings cycle begins.
Contact [email protected] for any questions or corrections.
Joel South covers large-cap stocks, dividend investing, and major market trends, with a focus on earnings analysis, valuation, and turning complex data into actionable insights for investors.
He brings more than 15 years of experience as an investor and financial journalist, including 12 years at The Motley Fool, where he served as an investment analyst, Bureau Chief, and later led the Fool.com investing news desk. He has also co-hosted an investing podcast and appeared across TV and radio discussing market trends.
